HOME >> BIOLOGY >> NEWS
New therapeutic target for Alzheimer's could lead to drugs without side effects

It's been one hundred years since Alzheimer's disease was first described, and yet our best treatments in development for the disease are still highly toxic drugs. But new research from Rockefeller University, published in the Feb. 26 online edition of Proceedings of the National Academy of Sciences, has identified a therapeutic target, called casein kinase 1, that may be the key to halting the course of the disease. The findings, based on studies in mammalian cells, show that chemicals that block casein kinase 1 don't interfere with a closely connected essential pathway.

Alzheimer's disease is caused by a build-up of a small protein called beta-amyloid, which is formed when a larger protein is broken into pieces. But the enzyme that produces beta-amyloid is also responsible for cleavage of another protein called Notch. The problem with current drugs is that they block these enzymes to stop production of beta-amyloid, and in doing so they also block the cleavage of Notch -- which plays an important role in the development of healthy brain cells.

The new research, based on studies by lead author Marc Flajolet and from the Nobel Prize winning laboratory of Paul Greengard, director of the Fisher Center for Alzheimer's Disease Research at Rockefeller, has identified another protein, casein kinase 1, that controls the regulation of these enzymes. When the researchers block casein kinase 1, production of beta-amyloid proteins goes down, but Notch signaling is not affected.

"Studies of brain tissue from Alzheimer's patients have shown an increase in casein kinase 1 expression," says Greengard, Vincent Astor Professor and head of the Laboratory of Molecular and Cellular Neuroscience. "We found that the key enzymes involved in beta-amyloid production called BACE and gamma-secretase were targets of casein kinase 1, so we investigated what role it might be playing."

The scientists modified mouse cells to generate a form of casein k
'"/>

Contact: Kristine Kelly
kkelly@rockefeller.edu
212-327-7146
Rockefeller University
26-Feb-2007


Page: 1 2

Related biology news :

1. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
2. From clinical cancer research: rethinking therapeutic cancer vaccine trials
3. Sensitivity to diverse range of chemotherapeutic drugs linked to common pathway
4. New therapeutic insight into duchenne muscular dystrophy
5. Small molecule derived from Rb2/p130 could act as cancer therapeutic
6. Sphingolipids with therapeutic ends
7. VBI research offers potential route to diabetes therapeutics
8. Quiet revolution may herald new RNA therapeutics
9. Scientists discover two-component lantibiotic with therapeutic potential
10. Potential new therapeutic target for asthma, allergies and cancer
11. Chemical genomic screening identifies novel therapeutic strategies for cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... TORONTO (PRWEB) , ... July 17, 2020 , ... Commercial ... hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic ... competitive and price pressure is not going away and capturing full value from every ...
(Date:7/2/2020)... CITY, Calif. (PRWEB) , ... July 01, 2020 ... ... biotech company, presented its phase 1a findings of Neihulizumab, a biologic for the ... conference in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the ...
(Date:6/28/2020)... (PRWEB) , ... June 25, ... ... of enterprise software solutions for biopharmaceutical R&D, today announced that it has ... developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and clinical ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... ... radar transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and ... can drive one or two switches in a push-pull configuration; yielding fast fall ...
(Date:7/31/2020)... ... July 29, 2020 , ... The SDX® ... in 16 countries, has reached its 20th anniversary of worldwide use. Introduced in ... at top universities including University of Pennsylvania, University of Michigan, University of Maryland, ...
(Date:7/18/2020)... , ... July 16, 2020 , ... “We are thrilled ... Wave Bioactives. “It’s the only technology of its kind on the market and we ... onions with the protective capacity of traditional cultured ingredients, creating a natural way to ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... that Massachusetts Institute of Technology (MIT) has expanded the company’s exclusive license ... to move into the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 ...
Breaking Biology Technology:
Cached News: